KRTAP10-9: A Potential Drug Target and Biomarker (G386676)

Target Name: KRTAP10-9

NCBI ID: G386676

KRTAP10-9

KRTAP10-9: A Potential Drug Target and Biomarker

Keratin-associated protein 18.9 (KRTAP10-9) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has gained significant interest in the scientific community.

The protein KRTAP10-9 is a member of the Keratin family, which is known for their role in the development and maintenance of hair and nails. KRTAP10-9 is a 19.1 kDa protein that is expressed in various tissues, including skin, hair, nails, and the nervous system. Its function is not well understood, but it is known to be involved in the regulation of cell growth, differentiation, and survival.

One of the key features of KRTAP10-9 is its ability to interact with various signaling molecules, including TGF-β1, a well-known growth factor that plays a crucial role in cell growth and development. TGF-β1 has been shown to promote the growth and differentiation of cancer cells, and it is thought to contribute to the development of many diseases, including cancer.

KRTAP10-9 has also been shown to interact with several other signaling molecules, including FAK, PDGF-尾, and NF-kappa-B. These signaling molecules are involved in a wide range of cellular processes, including cell adhesion, migration, and survival.

The potential drug target for KRTAP10-9 is its role in the regulation of cell growth and differentiation, as well as its involvement in the development and progression of various diseases. Drugs that target KRTAP10-9 have the potential to treat a wide range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, KRTAP10-9 has also been shown to be a potential biomarker for several diseases. Its expression has been detected in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to be expressed in the brains of individuals with Alzheimer's disease and other neurodegenerative disorders.

The ability of KRTAP10-9 to interact with signaling molecules makes it an attractive target for drug research. Many drugs that are currently in use for cancer and other diseases work by inhibiting the activity of these signaling molecules. By targeting KRTAP10-9, drugs could potentially have a more targeted and effective effect on the disease.

In conclusion, KRTAP10-9 is a protein that has shown promise as a potential drug target and biomarker for a wide range of diseases. Its unique structure and function, as well as its potential interactions with signaling molecules, make it an attractive target for research into the development and treatment of various conditions. Further studies are needed to fully understand the role of KRTAP10-9 in these diseases and its potential as a drug or biomarker.

Protein Name: Keratin Associated Protein 10-9

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP10-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP10-9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets